爱德华兹(EW)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EW 爱德华兹

盘前交易 05-07 04:49:00 EDT

83.20

+0.29

+0.35%

最高83.59	最低81.32	成交量508.37万
今开82.73	昨收82.91	日振幅2.74%
总市值479.68亿	流通市值477.57亿	总股本5.77亿
成交额4.21亿	换手率0.89%	流通股本5.74亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EW","market":"US","secType":"STK","nameCN":"爱德华兹","latestPrice":83.2,"timestamp":1778097600000,"preClose":82.91,"halted":0,"volume":5083742,"delay":0,"changeRate":0.0034977686648173475,"floatShares":574000000,"shares":576541693,"eps":1.880677,"marketStatus":"盘前交易","change":0.29,"latestTime":"05-07 04:49:00 EDT","open":82.73,"high":83.59,"low":81.32,"amount":421320557.85394,"amplitude":0.027379,"askPrice":88.8,"askSize":300,"bidPrice":74.14,"bidSize":28,"shortable":3,"etf":0,"ttmEps":1.880677,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778160600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":83.2,"postHourTrading":{"tag":"盘后","latestPrice":83.6152,"preClose":83.2,"latestTime":"19:20 EDT","volume":76656,"amount":6377861.674,"timestamp":1778109611872,"change":0.4152,"changeRate":0.00499,"amplitude":0.00499},"volumeRatio":1.0237332913260506,"optionData":{"bulkOrders":[{"symbol":"EW","call":true,"expireDate":1789704000000,"strike":"100.0","timestamp":1778083300333,"price":1.05,"volume":1326,"amount":139230,"type":"-"}]},"impliedVol":0.3529,"impliedVolPercentile":0.724},"requestUrl":"/m/hq/s/EW","defaultTab":"news","newsList":[{"id":"2630388345","title":"华泰通信: 光纤光缆进入历史大周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2630388345","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630388345?lang=zh_cn&edition=full","pubTime":"2026-04-26 08:37","pubTimestamp":1777163820,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　25Q4以来，全球光纤光缆市场呈现“量价共振”态势。我们认为本轮光纤光缆景气周期的核心驱动力在于供给需求关系重构。市场认为光纤价格上涨会引发企业大规模扩产，而我们认为行业未来2年内新增有效供给有限，景气周期有望拉长。基于此，我们看好本轮需求周期高度与持续性有望超过上轮。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-04-26/doc-inhvupep0143387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4587","BK4551","AIPO","IE00BN0W2V16.EUR","SG9999013999.USD","ARTY","BK4585","IE00BN0W2T93.GBP","AGIX","AI","BK4543","LU0345774391.USD","SG9999001176.SGD","BLOK","BK4528","GDP","BK4082","CHAT","IE00BYQQ9H92.USD","BK4213","IE00BN0W2W23.USD","BK4588","SG9999001176.USD","DTCR","SGXZ57979304.SGD","IE00BFXG0V08.USD","LU0345774631.USD","BK4504","BK4567","AIYY","BK4023","EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170319885","title":"异动解读 | 分析师上调目标价，爱德华兹盘中大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170319885","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170319885?lang=zh_cn&edition=full","pubTime":"2026-04-24 21:43","pubTimestamp":1777038226,"startTime":"0","endTime":"0","summary":"爱德华兹生命科学公司（股票代码：EW）今日盘中股价大幅上涨5.26%，引起了市场的广泛关注。消息面上，多家华尔街分析师发布了关于该公司的研究报告并调整了目标价。其中，瑞穗证券将爱德华兹生命科学公司的目标价从95美元上调至100美元，Truist证券也将目标价从89美元上调至90美元。分析师上调目标价通常反映了对公司未来业绩的乐观预期，这被认为是推动股价上涨的主要动力。尽管康科德金融将其目标价从87美元小幅下调至85美元，但市场整体反应积极，显示出投资者更看重积极的分析师观点。这些分析师评级调整共同影响了市场情绪，带动了爱德华兹股价在交易时段内的显著上扬。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158056026","title":"异动解读 | 爱德华兹盘前大涨5.24%，因瑞穗证券上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1158056026","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158056026?lang=zh_cn&edition=full","pubTime":"2026-04-24 20:40","pubTimestamp":1777034437,"startTime":"0","endTime":"0","summary":"爱德华兹生命科学公司今日盘前股价大幅上涨5.24%，引起了市场的关注。消息面上，根据华尔街分析师发布的研究报告，瑞穗证券将爱德华兹生命科学公司的目标价从95美元上调至100美元，同时Truist证券也将目标价从89美元上调至90美元。分析师上调目标价通常反映了对公司未来业绩的乐观预期，这可能是推动股价上涨的主要原因。尽管康科德金融将目标价从87美元小幅下调至85美元，但市场整体反应积极，显示出投资者更看重积极的分析师观点。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168620005","title":"爱德华兹生命科学公司上调全年调整后每股收益指引中值 新区间定为2.95至3.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168620005","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168620005?lang=zh_cn&edition=full","pubTime":"2026-04-24 04:41","pubTimestamp":1776976901,"startTime":"0","endTime":"0","summary":"爱德华兹生命科学公司宣布调整其全年财务指引，将调整后每股收益的预测区间更新为2.95美元至3.05美元。这一调整使得指引范围的中值得到显著提升。\n此次上调反映出公司对核心业务增长的强劲信心，尤其是在结构性心脏病创新疗法领域的市场表现超出预期。新指引区间较先前预测有所扩大，为投资者提供了更明确的盈利预期框架。\n公司管理层强调，这一调整基于当前业务势头及产品管线进展，同时考虑了全球医疗市场动态变化。持续的技术创新和临床需求增长成为推动业绩向好的关键动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4082","IE00BN0W2V16.EUR","BK4567","EW","IE00BYQQ9H92.USD","SG9999001176.USD","SG9999013999.USD","IE00BN0W2W23.USD","SG9999001176.SGD","BK4504","IE00BFXG0V08.USD","BK4588","LU0345774631.USD","LU0345774391.USD","SGXZ57979304.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174053798","title":"财报前瞻｜爱德华兹本季度营收预计增13.92%，毛利率与净利率指引待披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1174053798","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174053798?lang=zh_cn&edition=full","pubTime":"2026-04-17 00:12","pubTimestamp":1776355929,"startTime":"0","endTime":"0","summary":"市场一致预期显示，本季度爱德华兹收入预计为15.96亿美元，同比增长13.92%，EBIT预计为4.67亿美元，同比增长22.10%，调整后每股收益预计为0.73美元，同比增长21.77%；本季度毛利率与净利润或净利率的一致预期未见披露，暂不展示并以公司正式口径为准。上季度公司营收15.70亿美元，同比增长13.26%；毛利率78.15%；归属于母公司股东的净利润9,120.00万美元，净利率5.81%；调整后每股收益0.58美元，同比下降1.70%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜爱德华兹本季度营收预计增13.92%，毛利率与净利率指引待披露","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614099362","title":"Edwards Lifesciences旗下心血管耗材类产品获FDA批准，注册证号为P150048 S097","url":"https://stock-news.laohu8.com/highlight/detail?id=2614099362","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614099362?lang=zh_cn&edition=full","pubTime":"2026-02-26 13:54","pubTimestamp":1772085240,"startTime":"0","endTime":"0","summary":"产品名称：TRIFORMIS RESILIA Tricuspid Valve, Model 11300T，所属单位：Edwards Lifesciences，产品类型：心血管耗材，产品详情：TRIFORMIS RESILIA Tricuspid Valve, 型号11300T是一种带支架三叶式人工心脏瓣膜，采用RESILIA 牛心包组织制成。审批机构：FDA，证件类型：三类，注册证编号：P150048 S097，获批时间：2026-02-06","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226135423a4ca1f23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226135423a4ca1f23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4567","LU0345774631.USD","EW","IE00BYQQ9H92.USD","SGXZ57979304.SGD","IE00BN0W2W23.USD","BK4504","SG9999001176.USD","SG9999013999.USD","BK4588","IE00BN0W2T93.GBP","BK4585","SG9999001176.SGD","LU0345774391.USD","IE00BFXG0V08.USD","IE00BN0W2V16.EUR","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183560134","title":"欧盟反垄断监管机构终止对爱德华兹生命科学调查 因公司撤销仿制药限制政策","url":"https://stock-news.laohu8.com/highlight/detail?id=1183560134","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183560134?lang=zh_cn&edition=full","pubTime":"2026-02-16 18:45","pubTimestamp":1771238722,"startTime":"0","endTime":"0","summary":"欧盟反垄断监管机构已正式结束对爱德华兹生命科学（Edwards Lifesciences）的反垄断调查。此次调查的终止源于该公司主动撤销了其旨在限制仿制药竞争的相关政策。\n监管机构表示，随着企业自行取消引发争议的防抄袭条款，针对该医疗设备制造商的反竞争行为审查已无继续必要。这一决定标志着欧盟在维护医疗市场公平竞争方面取得关键进展。\n爱德华兹生命科学此番政策调整，将有助于促进心血管医疗器械领域的良性竞争，最终使患者能够以更合理的价格获得创新医疗产品。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYQQ9H92.USD","SG9999001176.USD","LU0345774391.USD","BK4588","IE00BN0W2V16.EUR","SG9999001176.SGD","SG9999013999.USD","BK4585","BK4082","BK4504","BK4567","EW","LU0345774631.USD","IE00BFXG0V08.USD","SGXZ57979304.SGD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142794786","title":"爱德华兹生命科学公司：对实现2026年8%-10%销售增长指引及每股收益2.90-3.05美元目标信心增强","url":"https://stock-news.laohu8.com/highlight/detail?id=1142794786","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142794786?lang=zh_cn&edition=full","pubTime":"2026-02-11 05:17","pubTimestamp":1770758232,"startTime":"0","endTime":"0","summary":"爱德华兹生命科学公司近日透露，其管理层对达成2026年财务目标的信心显著提升。根据最新评估，公司预计将实现8%至10%的年度销售增长率指引，同时每股收益目标区间维持在2.90美元到3.05美元之间。\n这一积极展望源于核心产品线的持续市场渗透及创新技术的商业化进展。随着全球医疗需求的结构性增长，公司在心脏瓣膜治疗领域的领先地位进一步巩固，为中长期增长注入强劲动能。\n当前，资本市场对医疗科技板块的关注度持续升温。爱德华兹通过精准的战略布局与高效的运营体系，正逐步将临床优势转化为可持续的财务回报。此次信心升级也反映出管理层对宏观环境波动与行业竞争格局的审慎乐观态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","EW","SG9999001176.SGD","SG9999001176.USD","IE00BN0W2V16.EUR","IE00BYQQ9H92.USD","BK4082","SGXZ57979304.SGD","BK4585","SG9999013999.USD","IE00BFXG0V08.USD","IE00BN0W2W23.USD","LU0345774631.USD","BK4504","BK4567","IE00BN0W2T93.GBP","LU0345774391.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184546999","title":"财报前瞻｜爱德华兹本季度营收预计增13.90%，机构观点待披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1184546999","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184546999?lang=zh_cn&edition=full","pubTime":"2026-02-03 10:12","pubTimestamp":1770084776,"startTime":"0","endTime":"0","summary":"爱德华兹将在2026年02月10日发布最新季度财报，市场关注本季度营收与盈利的同比改善，以及心血管介入业务的持续动能。市场一致预期显示，爱德华兹本季度总收入预计为15.46亿美元，同比增长13.90%；毛利率、净利率、调整后每股收益的公司层面指引若未披露则不展示；同时预测本季度EBIT为3.97亿美元，同比增长12.99%，调整后每股收益预计为0.62美元，同比增长11.51%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜爱德华兹本季度营收预计增13.90%，机构观点待披露","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607177704","title":"大摩：下调中资电讯股评级至“中性” 过去多年上升周期的驱动因素已结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2607177704","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607177704?lang=zh_cn&edition=full","pubTime":"2026-01-29 13:56","pubTimestamp":1769666214,"startTime":"0","endTime":"0","summary":"美国在2026年上半年将进一步降息，该行将大中华电信营运商评级下调至“中性”。该行指，中资电讯商多年的上升周期驱动因素——包括监管放松、竞争减弱、云业务份额提升及股东回报的基本面素已经过去。该行将中资电讯股H股评级下调至“与大市同步”，偏好固网多于移动，并偏好H股多于A股，因为人民币走强以及A股溢价可能收窄。该行预期中资电讯H股在2026年的目标股息率为6-7%，并继续偏好排序：中国电信>联通>中国移动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0164880469.USD","LU0039217434.USD","LU0531971595.HKD","LU1226287529.USD","BK1536","LU0149721374.USD","LU1497733557.USD","LU1226287792.SGD","LU1634259391.SGD","LU0164865239.USD","HK0000500386.USD","EW","00762","LU1064130708.USD","LU1951186391.HKD","HK0000352382.USD","LU1993786604.SGD","BK1506","00941","BK4585","HK0000352291.HKD","LU1960683339.HKD","BK1610","LU0067412154.USD","SG9999002463.SGD","80883","BK1152","LU1008478684.HKD","00728","LU1152091168.USD","BK1589","LU1497733631.SGD","LU1634259557.SGD","IE00BN0W2T93.GBP","LU0345774391.USD","LU1152091754.HKD","LU1226288170.HKD","LU1807302812.USD","SG9999013999.USD","LU1226287875.USD","HK0000288784.HKD","IE00BN0W2V16.EUR","LU0345774631.USD","LU0880133367.SGD","BK4504","IE00BN0W2W23.USD","IE00BYQQ9H92.USD","LU1497734951.SGD","LU1522347837.USD","LU1226288253.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121332365","title":"法院批准美国联邦贸易委员会请求，阻止爱德华兹生命科学收购杰纳阀技术公司——法庭记录","url":"https://stock-news.laohu8.com/highlight/detail?id=1121332365","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121332365?lang=zh_cn&edition=full","pubTime":"2026-01-10 05:08","pubTimestamp":1767992900,"startTime":"0","endTime":"0","summary":"根据最新法庭文件披露，一名法官已正式批准美国联邦贸易委员会（FTC）提出的紧急禁令请求，勒令暂停爱德华兹生命科学对杰纳阀技术公司的收购交易。这一裁决意味着两家医疗器械企业间的并购案将暂时受阻，等待进一步法律审查。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BN0W2T93.GBP","BK4585","EW","SG9999001176.SGD","SGXZ57979304.SGD","LU0345774391.USD","BK4082","IE00BN0W2W23.USD","LU0345774631.USD","IE00BYQQ9H92.USD","BK4504","IE00BN0W2V16.EUR","SG9999013999.USD","BK4567","SG9999001176.USD","IE00BFXG0V08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100154289","title":"FDA批准爱德华兹Sapien M3二尖瓣置换系统为首个经隔膜导管治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1100154289","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100154289?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:00","pubTimestamp":1766498443,"startTime":"0","endTime":"0","summary":"FDA批准爱德华兹的Sapien M3二尖瓣置换系统，成为首个经隔膜导管治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","IE00BFXG0V08.USD","LU0345774631.USD","IE00BYQQ9H92.USD","SG9999013999.USD","IE00BN0W2V16.EUR","BK4504","EW","BK4588","BK4567","IE00BN0W2W23.USD","LU0345774391.USD","SG9999001176.USD","SG9999001176.SGD","BK4585","IE00BN0W2T93.GBP","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127804047","title":"爱德华兹在年度投资者会议上重申可持续差异化增长战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1127804047","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127804047?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:02","pubTimestamp":1764856942,"startTime":"0","endTime":"0","summary":"爱德华兹在年度投资者会议上重申可持续差异化增长战略","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","IE00BN0W2V16.EUR","LU0345774631.USD","BK4504","IE00BN0W2T93.GBP","LU0345774391.USD","BK4588","BK4585","IE00BN0W2W23.USD","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","BK4082","EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512998291","title":"爱德华兹生命科学：2024年业绩符合市场预期 关注新品放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2512998291","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512998291?lang=zh_cn&edition=full","pubTime":"2025-02-17 00:00","pubTimestamp":1739721600,"startTime":"0","endTime":"0","summary":"2024 年业绩符合市场预期公司公布2024 全年业绩：剔除剥离业务后，收入54.40 亿美元，同比+8.6%；经调整EPS 2.43 美元，2023 年同口径为2.22 美元。公司表示12024 年全球范围内竞争格局和产品单价维持稳定，公司预计2025 年TAVR 收入同比增长5-7%。2024 全年,TMTT收入3.52 亿美元，同比+78%；其中4 季度收入1.05 亿美元，环比+15%，同比+88%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217105125abd1a46d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217105125abd1a46d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","BK4504","IE00BFXG0V08.USD","IE00BN0W2V16.EUR","BK4082","IE00BYQQ9H92.USD","BK4567","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511246075","title":"巴克莱：维持Edwards Lifesciences(EW.US)评级，由增持调整至增持评级, 目标价由88.00美元调整至90.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511246075","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511246075?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:42","pubTimestamp":1739461331,"startTime":"0","endTime":"0","summary":"巴克莱：维持Edwards Lifesciences(EW.US)评级，由增持调整至增持评级, 目标价由88.00美元调整至90.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13234248149780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110115529","title":"异动解读 | 爱德华公司业绩超预期,主导产品需求旺盛,股价盘中大涨5.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110115529","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110115529?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:40","pubTimestamp":1739371242,"startTime":"0","endTime":"0","summary":"医疗设备制造商爱德华生命科学公司(EW)今日盘中大涨5.93%,引发市场关注。\n公司旗舰产品TAVR设备第四季度销售额高达10.4亿美元,超过市场预期。这一主导产品的需求旺盛,推动公司第四季度整体业绩表现优于市场预期,成为推动该股上涨的主因。\n同时,多家分析师考虑到TAVR潜在保险覆盖范围扩大、手术批准范围加大,以及新产品Sapien M3获批上市等利好因素,上调了对该公司的评级,这也使投资者对其长期发展前景更加看好,进一步推升股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 爱德华公司业绩超预期,主导产品需求旺盛,股价盘中大涨5.93%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510308553","title":"爱德华生命科学盘中异动 早盘急速上涨5.42%报74.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510308553","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510308553?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:30","pubTimestamp":1739370635,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日22时30分，爱德华生命科学股票出现异动，股价大幅拉升5.42%。截至发稿，该股报74.75美元/股，成交量10.7285万股，换手率0.02%，振幅0.58%。爱德华生命科学股票所在的医疗器械行业中，整体涨幅为0.00%。其相关个股中，Rapid Micro Biosystems, Inc.、爱德华生命科学、Nuwellis, Inc.涨幅较大，Tivic Health Systems, Inc.、Lifeward Ltd.、Bluejay Diagnostics, Inc.较为活跃，换手率分别为449.66%、1.22%、1.05%，振幅较大的相关个股有908 Devices Inc.、Nuwellis, Inc.、Butterfly Network, Inc.，振幅分别为3.29%、3.25%、1.58%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212223035abcc5cde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212223035abcc5cde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","EW","IE00BN0W2W23.USD","BK4588","BK4082","BK4567","IE00BFXG0V08.USD","BK4504","IE00BYQQ9H92.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156540663","title":"异动解读 | 爱德华兹第四季度业绩喜人,股价盘后大涨7.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156540663","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156540663?lang=zh_cn&edition=full","pubTime":"2025-02-12 05:42","pubTimestamp":1739310152,"startTime":"0","endTime":"0","summary":"爱德华兹生命科学公司今日盘后股价大涨7.18%,引发市场广泛关注。消息面上,爱德华兹公司2024年第四季度业绩表现亮眼,成为推动股价上涨的主要原因。财报数据显示,第四季度该公司每股收益为0.59美元,超出市场预期的0.55美元;销售额达到13.9亿美元,也高于预期的13.58亿美元。业绩增长主要得益于该公司核心产品人工心脏瓣膜等医疗设备的销售持续旺盛。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123170331","title":"爱德华兹生命科学公司2024年第四季度每股收益$0.59，超过预期$0.55，销售额$13.9亿，超过预期$13.58亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1123170331","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123170331?lang=zh_cn&edition=full","pubTime":"2025-02-12 05:20","pubTimestamp":1739308823,"startTime":"0","endTime":"0","summary":"爱德华兹生命科学公司2024年第四季度每股收益$0.59，超过预期$0.55，销售额$13.9亿，超过预期$13.58亿。以上内容来自Benzinga Earnings专栏，原文如下：Edwards Lifesciences Q4 2024 Adj. EPS $0.59 Beats $0.55 Estimate, Sales $1.39B Beat $1.358B Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"爱德华兹生命科学公司2024年第四季度每股收益$0.59，超过预期$0.55，销售额$13.9亿，超过预期$13.58亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507528636","title":"爱德华生命科学盘中异动 快速上涨5.00%报72.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507528636","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507528636?lang=zh_cn&edition=full","pubTime":"2025-01-29 04:02","pubTimestamp":1738094521,"startTime":"0","endTime":"0","summary":"北京时间2025年01月29日04时02分，爱德华生命科学股票出现波动，股价急速上涨5.00%。截至发稿，该股报72.66美元/股，成交量390.587万股，换手率0.66%，振幅5.26%。爱德华生命科学股票所在的医疗器械行业中，整体跌幅为0.27%。爱德华生命科学公司简介：爱德华生命科学公司于2000年从百特国际分离出来，设计、制造和销售一系列用于晚期结构性心脏病的医疗器械和设备。该公司约55%的总销售额来自美国以外地区。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012904020198758e58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025012904020198758e58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","EW","IE00BN0W2V16.EUR","IE00BYQQ9H92.USD","BK4082","BK4585","IE00BFXG0V08.USD","IE00BN0W2W23.USD","BK4504","BK4567","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.edwards.com","stockEarnings":[{"period":"1week","weight":0.0244},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0653},{"period":"6month","weight":-0.0023},{"period":"1year","weight":0.1105},{"period":"ytd","weight":-0.024}],"compareEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.1137},{"period":"3month","weight":0.083},{"period":"6month","weight":0.0937},{"period":"1year","weight":0.3132},{"period":"ytd","weight":0.0761}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"爱德华兹生命科学公司于1999年9月10日在特拉华州注册成立。公司在结构性心脏病以及重症监护和外科监护方面处于全球领先地位。在帮助患者的热情驱使下，公司与世界领先的临床医生和研究人员合作，投资研发，以改变对结构性心脏病患者的护理，或在手术或重症监护期间需要血流动力学监测的患者的护理。","yearOnYearQuotes":[{"month":1,"riseRate":0.576923,"avgChangeRate":0.018112},{"month":2,"riseRate":0.576923,"avgChangeRate":0.014785},{"month":3,"riseRate":0.72,"avgChangeRate":0.019095},{"month":4,"riseRate":0.653846,"avgChangeRate":0.033225},{"month":5,"riseRate":0.703704,"avgChangeRate":0.031345},{"month":6,"riseRate":0.653846,"avgChangeRate":0.034615},{"month":7,"riseRate":0.576923,"avgChangeRate":0.004011},{"month":8,"riseRate":0.653846,"avgChangeRate":0.017986},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.008871},{"month":10,"riseRate":0.5,"avgChangeRate":-0.02835},{"month":11,"riseRate":0.692308,"avgChangeRate":0.033175},{"month":12,"riseRate":0.615385,"avgChangeRate":0.042291}],"exchange":"NYSE","name":"爱德华兹","nameEN":"Edwards Lifesciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"爱德华兹(EW)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供爱德华兹(EW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"爱德华兹,EW,爱德华兹股票,爱德华兹股票老虎,爱德华兹股票老虎国际,爱德华兹行情,爱德华兹股票行情,爱德华兹股价,爱德华兹股市,爱德华兹股票价格,爱德华兹股票交易,爱德华兹股票购买,爱德华兹股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"爱德华兹(EW)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供爱德华兹(EW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}